This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer

This study has been terminated.
(According to the protocol, the sponsor terminated the study after it was determined that less than 2 of the first 22 patients showed a PSA50 response.)
Information provided by (Responsible Party):
Incyte Corporation Identifier:
First received: March 12, 2008
Last updated: January 20, 2012
Last verified: January 2012
This is a clinical trial of orally administered Ruxolitinib (INCB018424) in patients whose disease has progressed following 1 prior chemotherapy regimen (not including anti-androgens or ketoconazole) for metastatic, androgen-independent prostate cancer.

Condition Intervention Phase
Metastatic Prostate Cancer Drug: Ruxolitinib Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Open-Label Study of INCB018424 Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer

Resource links provided by NLM:

Further study details as provided by Incyte Corporation:

Primary Outcome Measures:
  • Number of Participants With a Prostate-specific Antigen Response [ Time Frame: Assessed monthly from Baseline until the end of study (up to 8 months) ]
    A prostate-specific antigen (PSA) response was defined as a PSA decline from Baseline of 50% or greater, repeated on 2 occasions at least 4 weeks apart.

  • Number of Participants With Adverse Events (AE) [ Time Frame: From Baseline through to the end of study (up to 8 months) ]
    A treatment-related AE was defined as an event with a definite, probable, or possible causality to study medication. A serious AE is an event resulting in death, hospitalization, persistent or significant disability/incapacity, or is life threatening, a congenital anomaly/birth defect or requires medical or surgical intervention to prevent 1 of the outcomes above. The intensity of an AE was graded according to the National Cancer Institute common terminology criteria for adverse events (NCI-CTCAE) version 3.0: Grade 1 (Mild); Grade 2 (Moderate); Grade 3 (Severe); Grade 4 (life-threatening).

Secondary Outcome Measures:
  • Time to Progression [ Time Frame: From Baseline until the end of study (up to 8 months). ]

    The time from first dosing day to the date of disease progression:

    • Progressive measurable disease by RECIST criteria (regardless of bone scan or prostate-specific antigen (PSA) results).
    • Development of unequivocal new lesions on bone scan without clinical suspicion of a "flare" reaction.
    • In patients who responded or had a decreased PSA from Baseline, a rise of 50% from PSA nadir, if the increase is ≥ 5 ng/mL or back to Baseline and confirmed by a 2nd value.
    • In patients with no decrease in PSA from Baseline, a 25% rise over Baseline and ≥ 5 ng/mL confirmed by a 2nd value.

  • Number of Participants With a Complete Response or Partial Response [ Time Frame: From Baseline through the end of study (up to 8 months) ]
    Complete Response (CR) and Partial Response (PR) defined by the Response Evaluation Criteria in Solid Tumor (RECIST) criteria. CR: Disappearance of all target and nontarget lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter, or persistence of 1 or more nontarget lesion(s) or/and maintenance of tumor marker level above the normal limits.

Enrollment: 22
Study Start Date: February 2008
Study Completion Date: January 2009
Primary Completion Date: January 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ruxolitinib
Participants received ruxolitinib 25 mg orally twice daily in 12-hour intervals for 21-day cycles for as long as the study medication was tolerated and provided clinical benefit.
Drug: Ruxolitinib
Ruxolitinib 25 mg tablets taken with water twice a day.
Other Name: INCB018424


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosed with radiographically-documented metastatic prostate cancer that has progressed while receiving androgen-suppressive therapy in the form of a bilateral orchiectomy or Gonadotropin-Releasing Hormone (GnRH) agonist (eg, leuprolide, goserelin).
  • Patients must demonstrate evidence of progressive disease based on 1 of the following criteria: 1) Progressive measurable disease, or 2) Progressive rise in prostate-specific antigen (PSA) level (2 consecutive rises from a prior reference level), or 3) Development of new lesions on bone scan.
  • If receiving a GnRH agonist as primary hormonal therapy, the serum testosterone level must be ≤ 50 ng/mL.
  • Must have received and progressed during or following 1 prior chemotherapy regimen for metastatic disease (not including an anti-androgen or ketoconazole); or, must have discontinued prior systemic therapy because of poor tolerance or other adverse effects; or, must have refused chemotherapy treatment. Patients having undergone more than 1 prior chemotherapy regimen may be admitted at the discretion of the sponsor.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
  • Baseline serum PSA level of ≥ 10 ng/mL

Exclusion Criteria:

  • Received any anti-cancer medications in the 30 days before receiving their first dose of study medication except for GnRH agonists and bisphosphonates.
  • Any unresolved toxicity greater than or equal to Grade 2 from previous anti-cancer therapy, except for stable chronic toxicities not expected to resolve, such as peripheral neurotoxicity.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00638378

United States, California
Highland, California, United States
Montebello, California, United States
Mountain View, California, United States
United States, Illinois
Galesburg, Illinois, United States
United States, Kansas
Overland Park, Kansas, United States
Wichita, Kansas, United States
United States, Michigan
Grand Rapids, Michigan, United States
United States, Missouri
Jefferson City, Missouri, United States
United States, Montana
Great Falls, Montana, United States, 59405
United States, New Jersey
Cherry Hill, New Jersey, United States
United States, New York
Staten Island, New York, United States
United States, North Dakota
Bismarck, North Dakota, United States
United States, Pennsylvania
Bethlehem, Pennsylvania, United States
United States, South Carolina
Sumter, South Carolina, United States
United States, Washington
Lacey, Washington, United States
Sponsors and Collaborators
Incyte Corporation
  More Information

Responsible Party: Incyte Corporation Identifier: NCT00638378     History of Changes
Other Study ID Numbers: INCB 18424-254
Study First Received: March 12, 2008
Results First Received: December 15, 2011
Last Updated: January 20, 2012

Keywords provided by Incyte Corporation:
Prostate Cancer

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on August 18, 2017